European prize for mobile vaccination units The Netherlands’ mobile vaccination units (prikbussen) have been selected as a best-practice method for the European project ‘Overcoming Obstacles to Vaccination’.
RIVM modelling for COVID-19 reviewed by international experts An international audit committee of scientific experts, commissioned by the RIVM Scientific Advisory Board, reviewed the institute’s COVID-19 data analytics and modelling work. These models and data formed a scientific basis for recommendations by the Outbreak Management Team (OMT) and others on COVID-19 control measures in the Netherlands.
No reduction in number of young people with suicidal thoughts Even after a period without any coronavirus measures, the number of young people (aged 12-25 years) with serious suicidal thoughts remains high (16%). After nearly doubling in the last lockdown period (from 9% in autumn 2021 to 17% between December 2021 and February 2022), there has been almost no reduction in this percentage.
RIVM creates overview of nitrogen monitoring in water in Europe At the behest of the European Parliament, the National Institute for Public Health and the Environment (RIVM) has formulated a report on how EU member states are dealing with European regulations on nitrogen in water (nitrate). Michel Looyenstein
Autumn wave of COVID-19 may be starting: vaccination and testing are key Infections with the coronavirus SARS-CoV-2 in the Netherlands have been increasing for the past few weeks. Hospital admissions are also on the rise.
Effect of air cleaners on COVID-19 not yet clear It is not yet clear whether air cleaners that can be moved around actually help to reduce transmission of the coronavirus SARS-CoV-2. These findings are from a literature review conducted by RIVM.
Hypersensitivity reactions to fillers may occur after COVID-19 vaccination People may experience hypersensitivity reactions to fillers following a COVID-19 vaccination.
Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.